Your browser doesn't support javascript.
loading
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
Schwarzer, R; Kivaranovic, D; Paternostro, R; Mandorfer, M; Reiberger, T; Trauner, M; Peck-Radosavljevic, M; Ferlitsch, A.
Afiliación
  • Schwarzer R; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Kivaranovic D; Vienna Hepatic Haemodynamic Lab, Vienna, Austria.
  • Paternostro R; Department of Statistics and Operations Research, University of Vienna, Vienna, Austria.
  • Mandorfer M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Reiberger T; Vienna Hepatic Haemodynamic Lab, Vienna, Austria.
  • Trauner M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Peck-Radosavljevic M; Vienna Hepatic Haemodynamic Lab, Vienna, Austria.
  • Ferlitsch A; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Aliment Pharmacol Ther ; 47(8): 1162-1169, 2018 Apr.
Article en En | MEDLINE | ID: mdl-29492989
BACKGROUND: Sequential measurements of hepatic venous pressure gradient (HVPG) are used to assess the haemodynamic response to nonselective betablockers (NSBBs) in patients with portal hypertension. AIMS: To assess the rates of HVPG response to different doses of carvedilol. METHODS: Consecutive patients with cirrhosis undergoing HVPG-guided carvedilol therapy for primary prophylaxis of variceal bleeding between 08/2010 and 05/2015 were retrospectively included. After baseline HVPG measurement, carvedilol 6.25 mg/d was administered and HVPG response (HVPG-decrease ≥20% or to ≤12 mm Hg) was assessed after 3-4 weeks. In case of nonresponse, carvedilol dose was increased to 12.5 mg/d and a third HVPG-measurement was performed after 3-4 weeks. We also assessed HVPG-response rates according to the Baveno VI consensus (HVPG decrease ≥10% or to ≤12 mm Hg) and changes in systolic arterial pressure (SAP). RESULTS: Seventy-two patients (Child A, 37%; B, 35%; C, 28%) were included. 28 (39%) patients achieved a HVPG-decrease ≥ 20% with carvedilol 6.25 mg/d and another 10 (14%) with carvedilol 12.5 mg/d. Forty (56%) patients had a HVPG decrease ≥10% with carvedilol 6.25 mg/d and 24 (33%) with carvedilol 12.5 mg/d. Thus, in total, a HVPG-response of ≥20% and ≥10% and was achieved in 38 (53%) and 55 (76%) and of patients respectively. Notably, 6 patients (n = 4 with ascites) did not tolerate an increase to 12.5 mg/d due to hypotension/bradycardia. However, none of the other patients had a SAP < 90 mm Hg at the final HVPG measurement. CONCLUSION: Carvedilol 12.5 mg/d was more effective than 6.25 mg/d in decreasing HVPG in primary prophylaxis. A total of 76% of patients achieved a HVPG-response of ≥ 10% to carvedilol 12.5 mg/d, however, arterial hypotension might occur, especially in patients with ascites.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Várices Esofágicas y Gástricas / Presión Portal / Carvedilol / Hemorragia Gastrointestinal / Hipertensión Portal / Antihipertensivos Tipo de estudio: Observational_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Várices Esofágicas y Gástricas / Presión Portal / Carvedilol / Hemorragia Gastrointestinal / Hipertensión Portal / Antihipertensivos Tipo de estudio: Observational_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido